ArticleBlood cancer journal2023

Exploiting PRMT5 as a target for combination therapy in mantle cell lymphoma characterized by frequent ATM and TP53 mutations.

Yuxuan Che et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.